Johnson & Johnson (NYSE:JNJ) reported its first-quarter results ahead of expectations, with the beat driven by higher sales from its Innovative Medicine segment.
• Johnson & Johnson stock is trending lower. Why is JNJ stock trading lower?
The latest results “set the stage for greater potential upside ahead,” as the company’s revenue and earnings growth are likely to accelerate through the year and the back half of the decade, according to Guggenheim Securities.
The Johnson & Johnson Analyst: Analyst Vamil Divan maintained a Buy rating on the stock.
The Johnson & Johnson Thesis: The company reported total sales of $24.06 billion and earnings of $2.70 per share, beating consensus estimates of $23.61 billion and $2.68 per share, respectively, Divan said in the …